Advertisement

Index by author

October 01, 1995; Volume 48,Issue 4

A

  1. Abdel-Megeed, M

    1. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
      M Gupta, M Abdel-Megeed, Y Hoki, G Kohlhagen, K Paull and Y Pommier
      Molecular Pharmacology October 1995, 48 (4) 658-665;

  2. Alexander, R W

    1. Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation.
      B Lassègue, R W Alexander, G Nickenig, M Clark, T J Murphy and K K Griendling
      Molecular Pharmacology October 1995, 48 (4) 601-609;

  3. Alvarez, R

    1. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3.
      R Alvarez, C Sette, D Yang, R M Eglen, R Wilhelm, E R Shelton and M Conti
      Molecular Pharmacology October 1995, 48 (4) 616-622;

  4. Anand, R

    1. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors.
      V Gerzanich, X Peng, F Wang, G Wells, R Anand, S Fletcher and J Lindstrom
      Molecular Pharmacology October 1995, 48 (4) 774-782;

B

  1. Bakthavachalam, V

    1. Structural and ligand recognition properties of imidazoline binding proteins in tissues of rat and rabbit.
      B Lanier, R Raddatz, V Bakthavachalam, I Coupry, J L Neumeyer and S M Lanier
      Molecular Pharmacology October 1995, 48 (4) 703-710;

  2. Barnard, E A

    1. Localization of P2X purinoceptor transcripts in the rat nervous system.
      E J Kidd, C B Grahames, J Simon, A D Michel, E A Barnard and P P Humphrey
      Molecular Pharmacology October 1995, 48 (4) 569-573;

  3. Barnes, P J

    1. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
      P M Seldon, P J Barnes, K Meja and M A Giembycz
      Molecular Pharmacology October 1995, 48 (4) 747-757;

  4. Beck, W T

    1. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line.
      U G Bhat, M A Winter, H L Pearce and W T Beck
      Molecular Pharmacology October 1995, 48 (4) 682-689;

  5. Berghard, A

    1. Differential effects of a topoisomerase I inhibitor on dioxin inducibility and high-level expression of the cytochrome P450IA1 gene.
      K Gradin, R Toftgård and A Berghard
      Molecular Pharmacology October 1995, 48 (4) 610-615;

  6. Bhat, U G

    1. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line.
      U G Bhat, M A Winter, H L Pearce and W T Beck
      Molecular Pharmacology October 1995, 48 (4) 682-689;

  7. Bikker, J

    1. Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor.
      F Z Chung, L H Wu, Y Tian, M A Vartanian, H Lee, J Bikker, C Humblet, M C Pritchard, J Raphy and N Suman-Chauhan
      Molecular Pharmacology October 1995, 48 (4) 711-716;

  8. Blanner, P

    1. Structural requirements of analogues of polyamines for migration and growth of IEC-6 cells.
      S A McCormack, B J Zimmerman, M Israel, P Blanner and L R Johnson
      Molecular Pharmacology October 1995, 48 (4) 724-729;

  9. Buller, A L

    1. Glycine modulates ethanol inhibition of heteromeric N-methyl-D-aspartate receptors expressed in Xenopus oocytes.
      A L Buller, H C Larson, R A Morrisett and D T Monaghan
      Molecular Pharmacology October 1995, 48 (4) 717-723;

  10. Burnett, J P

    1. Cloning and expression of a human metabotropic glutamate receptor 1 alpha: enhanced coupling on co-transfection with a glutamate transporter.
      M A Desai, J P Burnett, N G Mayne and D D Schoepp
      Molecular Pharmacology October 1995, 48 (4) 648-657;

C

  1. Calmels, T P

    1. Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells.
      Z Pei, T P Calmels, C E Creutz and S M Sebti
      Molecular Pharmacology October 1995, 48 (4) 676-681;

  2. Chavany, C

    1. Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers.
      C Chavany, Y Connell and L Neckers
      Molecular Pharmacology October 1995, 48 (4) 738-746;

  3. Chen, G

    1. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
      G Chen, J E Wright and A Rosowsky
      Molecular Pharmacology October 1995, 48 (4) 758-765;

  4. Chung, F Z

    1. Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor.
      F Z Chung, L H Wu, Y Tian, M A Vartanian, H Lee, J Bikker, C Humblet, M C Pritchard, J Raphy and N Suman-Chauhan
      Molecular Pharmacology October 1995, 48 (4) 711-716;

  5. Ciaccio, P J

    1. Modulation of detoxification gene expression in human colon HT29 cells by glutathione-S-transferase inhibitors.
      P J Ciaccio, H Shen, A K Jaiswal, M H Lyttle and K D Tew
      Molecular Pharmacology October 1995, 48 (4) 639-647;

  6. Clark, M

    1. Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation.
      B Lassègue, R W Alexander, G Nickenig, M Clark, T J Murphy and K K Griendling
      Molecular Pharmacology October 1995, 48 (4) 601-609;

  7. Connell, Y

    1. Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers.
      C Chavany, Y Connell and L Neckers
      Molecular Pharmacology October 1995, 48 (4) 738-746;

  8. Conti, M

    1. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3.
      R Alvarez, C Sette, D Yang, R M Eglen, R Wilhelm, E R Shelton and M Conti
      Molecular Pharmacology October 1995, 48 (4) 616-622;

  9. Coupry, I

    1. Structural and ligand recognition properties of imidazoline binding proteins in tissues of rat and rabbit.
      B Lanier, R Raddatz, V Bakthavachalam, I Coupry, J L Neumeyer and S M Lanier
      Molecular Pharmacology October 1995, 48 (4) 703-710;

  10. Creutz, C E

    1. Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells.
      Z Pei, T P Calmels, C E Creutz and S M Sebti
      Molecular Pharmacology October 1995, 48 (4) 676-681;

D

  1. Delorey, T M

    1. Pharmacological subtypes of the gamma-aminobutyric acidA receptors defined by a gamma-aminobutyric acid analogue 4,5,6,7-tetrahydroisoxazolo[5,4-c] pyridin-3-ol and allosteric coupling: characterization using subunit-specific antibodies.
      K H Huh, T M Delorey, S Endo and R W Olsen
      Molecular Pharmacology October 1995, 48 (4) 666-675;

  2. Desai, M A

    1. Cloning and expression of a human metabotropic glutamate receptor 1 alpha: enhanced coupling on co-transfection with a glutamate transporter.
      M A Desai, J P Burnett, N G Mayne and D D Schoepp
      Molecular Pharmacology October 1995, 48 (4) 648-657;

E

  1. Eglen, R M

    1. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3.
      R Alvarez, C Sette, D Yang, R M Eglen, R Wilhelm, E R Shelton and M Conti
      Molecular Pharmacology October 1995, 48 (4) 616-622;

  2. Endo, S

    1. Pharmacological subtypes of the gamma-aminobutyric acidA receptors defined by a gamma-aminobutyric acid analogue 4,5,6,7-tetrahydroisoxazolo[5,4-c] pyridin-3-ol and allosteric coupling: characterization using subunit-specific antibodies.
      K H Huh, T M Delorey, S Endo and R W Olsen
      Molecular Pharmacology October 1995, 48 (4) 666-675;

F

  1. Fletcher, S

    1. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors.
      V Gerzanich, X Peng, F Wang, G Wells, R Anand, S Fletcher and J Lindstrom
      Molecular Pharmacology October 1995, 48 (4) 774-782;

  2. Forman, S A

    1. A discrete site for general anesthetics on a postsynaptic receptor.
      S A Forman, K W Miller and G Yellen
      Molecular Pharmacology October 1995, 48 (4) 574-581;

  3. Frazier, J S

    1. Phosphorylation of cyclic AMP response element-binding protein and induction of c-fos gene expression on withdrawal from chronic treatment with carbachol in NG108-15 cells.
      J M Thomas, J S Frazier, Z W Hu and B B Hoffman
      Molecular Pharmacology October 1995, 48 (4) 593-600;

G

  1. Gerzanich, V

    1. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors.
      V Gerzanich, X Peng, F Wang, G Wells, R Anand, S Fletcher and J Lindstrom
      Molecular Pharmacology October 1995, 48 (4) 774-782;

  2. Giasson, E

    1. Involvement of a tyrosine kinase pathway in the growth-promoting effects of angiotensin II on aortic smooth muscle cells.
      I Leduc, P Haddad, E Giasson and S Meloche
      Molecular Pharmacology October 1995, 48 (4) 582-592;

  3. Giembycz, M A

    1. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
      P M Seldon, P J Barnes, K Meja and M A Giembycz
      Molecular Pharmacology October 1995, 48 (4) 747-757;

  4. Gradin, K

    1. Differential effects of a topoisomerase I inhibitor on dioxin inducibility and high-level expression of the cytochrome P450IA1 gene.
      K Gradin, R Toftgård and A Berghard
      Molecular Pharmacology October 1995, 48 (4) 610-615;

  5. Grahames, C B

    1. Localization of P2X purinoceptor transcripts in the rat nervous system.
      E J Kidd, C B Grahames, J Simon, A D Michel, E A Barnard and P P Humphrey
      Molecular Pharmacology October 1995, 48 (4) 569-573;

  6. Griendling, K K

    1. Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation.
      B Lassègue, R W Alexander, G Nickenig, M Clark, T J Murphy and K K Griendling
      Molecular Pharmacology October 1995, 48 (4) 601-609;

  7. Gupta, M

    1. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
      M Gupta, M Abdel-Megeed, Y Hoki, G Kohlhagen, K Paull and Y Pommier
      Molecular Pharmacology October 1995, 48 (4) 658-665;

  8. Gustafsson, J A

    1. Developmental and endocrine regulation of P450 isoforms in rat breast.
      H Hellmold, J G Lamb, A Wyss, J A Gustafsson and M Warner
      Molecular Pharmacology October 1995, 48 (4) 630-638;

H

  1. Haddad, P

    1. Involvement of a tyrosine kinase pathway in the growth-promoting effects of angiotensin II on aortic smooth muscle cells.
      I Leduc, P Haddad, E Giasson and S Meloche
      Molecular Pharmacology October 1995, 48 (4) 582-592;

  2. Hellmold, H

    1. Developmental and endocrine regulation of P450 isoforms in rat breast.
      H Hellmold, J G Lamb, A Wyss, J A Gustafsson and M Warner
      Molecular Pharmacology October 1995, 48 (4) 630-638;

  3. Hoffman, B B

    1. Phosphorylation of cyclic AMP response element-binding protein and induction of c-fos gene expression on withdrawal from chronic treatment with carbachol in NG108-15 cells.
      J M Thomas, J S Frazier, Z W Hu and B B Hoffman
      Molecular Pharmacology October 1995, 48 (4) 593-600;

  4. Hoki, Y

    1. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
      M Gupta, M Abdel-Megeed, Y Hoki, G Kohlhagen, K Paull and Y Pommier
      Molecular Pharmacology October 1995, 48 (4) 658-665;

  5. Hu, Z W

    1. Phosphorylation of cyclic AMP response element-binding protein and induction of c-fos gene expression on withdrawal from chronic treatment with carbachol in NG108-15 cells.
      J M Thomas, J S Frazier, Z W Hu and B B Hoffman
      Molecular Pharmacology October 1995, 48 (4) 593-600;

  6. Huh, K H

    1. Pharmacological subtypes of the gamma-aminobutyric acidA receptors defined by a gamma-aminobutyric acid analogue 4,5,6,7-tetrahydroisoxazolo[5,4-c] pyridin-3-ol and allosteric coupling: characterization using subunit-specific antibodies.
      K H Huh, T M Delorey, S Endo and R W Olsen
      Molecular Pharmacology October 1995, 48 (4) 666-675;

  7. Humblet, C

    1. Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor.
      F Z Chung, L H Wu, Y Tian, M A Vartanian, H Lee, J Bikker, C Humblet, M C Pritchard, J Raphy and N Suman-Chauhan
      Molecular Pharmacology October 1995, 48 (4) 711-716;

  8. Humphrey, P P

    1. Localization of P2X purinoceptor transcripts in the rat nervous system.
      E J Kidd, C B Grahames, J Simon, A D Michel, E A Barnard and P P Humphrey
      Molecular Pharmacology October 1995, 48 (4) 569-573;

I

  1. Israel, M

    1. Structural requirements of analogues of polyamines for migration and growth of IEC-6 cells.
      S A McCormack, B J Zimmerman, M Israel, P Blanner and L R Johnson
      Molecular Pharmacology October 1995, 48 (4) 724-729;

J

  1. Jaiswal, A K

    1. Modulation of detoxification gene expression in human colon HT29 cells by glutathione-S-transferase inhibitors.
      P J Ciaccio, H Shen, A K Jaiswal, M H Lyttle and K D Tew
      Molecular Pharmacology October 1995, 48 (4) 639-647;

  2. Johnson, L R

    1. Structural requirements of analogues of polyamines for migration and growth of IEC-6 cells.
      S A McCormack, B J Zimmerman, M Israel, P Blanner and L R Johnson
      Molecular Pharmacology October 1995, 48 (4) 724-729;

K

  1. Kidd, E J

    1. Localization of P2X purinoceptor transcripts in the rat nervous system.
      E J Kidd, C B Grahames, J Simon, A D Michel, E A Barnard and P P Humphrey
      Molecular Pharmacology October 1995, 48 (4) 569-573;

  2. Kohlhagen, G

    1. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
      M Gupta, M Abdel-Megeed, Y Hoki, G Kohlhagen, K Paull and Y Pommier
      Molecular Pharmacology October 1995, 48 (4) 658-665;

L

  1. Lamb, J G

    1. Developmental and endocrine regulation of P450 isoforms in rat breast.
      H Hellmold, J G Lamb, A Wyss, J A Gustafsson and M Warner
      Molecular Pharmacology October 1995, 48 (4) 630-638;

  2. Lanier, B

    1. Structural and ligand recognition properties of imidazoline binding proteins in tissues of rat and rabbit.
      B Lanier, R Raddatz, V Bakthavachalam, I Coupry, J L Neumeyer and S M Lanier
      Molecular Pharmacology October 1995, 48 (4) 703-710;

  3. Lanier, S M

    1. Structural and ligand recognition properties of imidazoline binding proteins in tissues of rat and rabbit.
      B Lanier, R Raddatz, V Bakthavachalam, I Coupry, J L Neumeyer and S M Lanier
      Molecular Pharmacology October 1995, 48 (4) 703-710;

  4. Larson, H C

    1. Glycine modulates ethanol inhibition of heteromeric N-methyl-D-aspartate receptors expressed in Xenopus oocytes.
      A L Buller, H C Larson, R A Morrisett and D T Monaghan
      Molecular Pharmacology October 1995, 48 (4) 717-723;

  5. Lassègue, B

    1. Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation.
      B Lassègue, R W Alexander, G Nickenig, M Clark, T J Murphy and K K Griendling
      Molecular Pharmacology October 1995, 48 (4) 601-609;

  6. Leduc, I

    1. Involvement of a tyrosine kinase pathway in the growth-promoting effects of angiotensin II on aortic smooth muscle cells.
      I Leduc, P Haddad, E Giasson and S Meloche
      Molecular Pharmacology October 1995, 48 (4) 582-592;

  7. Lee, H

    1. Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor.
      F Z Chung, L H Wu, Y Tian, M A Vartanian, H Lee, J Bikker, C Humblet, M C Pritchard, J Raphy and N Suman-Chauhan
      Molecular Pharmacology October 1995, 48 (4) 711-716;

  8. Lindstrom, J

    1. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors.
      V Gerzanich, X Peng, F Wang, G Wells, R Anand, S Fletcher and J Lindstrom
      Molecular Pharmacology October 1995, 48 (4) 774-782;

  9. Lyttle, M H

    1. Modulation of detoxification gene expression in human colon HT29 cells by glutathione-S-transferase inhibitors.
      P J Ciaccio, H Shen, A K Jaiswal, M H Lyttle and K D Tew
      Molecular Pharmacology October 1995, 48 (4) 639-647;

M

  1. Mayne, N G

    1. Cloning and expression of a human metabotropic glutamate receptor 1 alpha: enhanced coupling on co-transfection with a glutamate transporter.
      M A Desai, J P Burnett, N G Mayne and D D Schoepp
      Molecular Pharmacology October 1995, 48 (4) 648-657;

  2. McCormack, S A

    1. Structural requirements of analogues of polyamines for migration and growth of IEC-6 cells.
      S A McCormack, B J Zimmerman, M Israel, P Blanner and L R Johnson
      Molecular Pharmacology October 1995, 48 (4) 724-729;

  3. Medzihradsky, F

    1. Reversible modulation of opioid receptor binding in intact neural cells by endogenous guanosine triphosphate.
      N Yabaluri and F Medzihradsky
      Molecular Pharmacology October 1995, 48 (4) 690-695;

  4. Meja, K

    1. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
      P M Seldon, P J Barnes, K Meja and M A Giembycz
      Molecular Pharmacology October 1995, 48 (4) 747-757;

  5. Meloche, S

    1. Involvement of a tyrosine kinase pathway in the growth-promoting effects of angiotensin II on aortic smooth muscle cells.
      I Leduc, P Haddad, E Giasson and S Meloche
      Molecular Pharmacology October 1995, 48 (4) 582-592;

  6. Michel, A D

    1. Localization of P2X purinoceptor transcripts in the rat nervous system.
      E J Kidd, C B Grahames, J Simon, A D Michel, E A Barnard and P P Humphrey
      Molecular Pharmacology October 1995, 48 (4) 569-573;

  7. Miller, K W

    1. A discrete site for general anesthetics on a postsynaptic receptor.
      S A Forman, K W Miller and G Yellen
      Molecular Pharmacology October 1995, 48 (4) 574-581;

  8. Monaghan, D T

    1. Glycine modulates ethanol inhibition of heteromeric N-methyl-D-aspartate receptors expressed in Xenopus oocytes.
      A L Buller, H C Larson, R A Morrisett and D T Monaghan
      Molecular Pharmacology October 1995, 48 (4) 717-723;

  9. Morrisett, R A

    1. Glycine modulates ethanol inhibition of heteromeric N-methyl-D-aspartate receptors expressed in Xenopus oocytes.
      A L Buller, H C Larson, R A Morrisett and D T Monaghan
      Molecular Pharmacology October 1995, 48 (4) 717-723;

  10. Murphy, T J

    1. Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation.
      B Lassègue, R W Alexander, G Nickenig, M Clark, T J Murphy and K K Griendling
      Molecular Pharmacology October 1995, 48 (4) 601-609;

N

  1. Neckers, L

    1. Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers.
      C Chavany, Y Connell and L Neckers
      Molecular Pharmacology October 1995, 48 (4) 738-746;

  2. Neumeyer, J L

    1. Structural and ligand recognition properties of imidazoline binding proteins in tissues of rat and rabbit.
      B Lanier, R Raddatz, V Bakthavachalam, I Coupry, J L Neumeyer and S M Lanier
      Molecular Pharmacology October 1995, 48 (4) 703-710;

  3. Nickenig, G

    1. Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation.
      B Lassègue, R W Alexander, G Nickenig, M Clark, T J Murphy and K K Griendling
      Molecular Pharmacology October 1995, 48 (4) 601-609;

  4. Nogami, M

    1. Lysophosphatidic acid regulation of cyclic AMP accumulation in cultured human airway smooth muscle cells.
      M Nogami, S M Whittle, D J Romberger, S I Rennard and M L Toews
      Molecular Pharmacology October 1995, 48 (4) 766-773;

O

  1. Olsen, R W

    1. Pharmacological subtypes of the gamma-aminobutyric acidA receptors defined by a gamma-aminobutyric acid analogue 4,5,6,7-tetrahydroisoxazolo[5,4-c] pyridin-3-ol and allosteric coupling: characterization using subunit-specific antibodies.
      K H Huh, T M Delorey, S Endo and R W Olsen
      Molecular Pharmacology October 1995, 48 (4) 666-675;

P

  1. Paull, K

    1. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
      M Gupta, M Abdel-Megeed, Y Hoki, G Kohlhagen, K Paull and Y Pommier
      Molecular Pharmacology October 1995, 48 (4) 658-665;

  2. Pearce, H L

    1. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line.
      U G Bhat, M A Winter, H L Pearce and W T Beck
      Molecular Pharmacology October 1995, 48 (4) 682-689;

  3. Pei, Z

    1. Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells.
      Z Pei, T P Calmels, C E Creutz and S M Sebti
      Molecular Pharmacology October 1995, 48 (4) 676-681;

  4. Peng, X

    1. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors.
      V Gerzanich, X Peng, F Wang, G Wells, R Anand, S Fletcher and J Lindstrom
      Molecular Pharmacology October 1995, 48 (4) 774-782;

  5. Perez, J

    1. Presynaptic Ca2+/calmodulin-dependent protein kinase II: autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake.
      M Popoli, C Vocaturo, J Perez, E Smeraldi and G Racagni
      Molecular Pharmacology October 1995, 48 (4) 623-629;

  6. Pommier, Y

    1. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
      M Gupta, M Abdel-Megeed, Y Hoki, G Kohlhagen, K Paull and Y Pommier
      Molecular Pharmacology October 1995, 48 (4) 658-665;

  7. Popoli, M

    1. Presynaptic Ca2+/calmodulin-dependent protein kinase II: autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake.
      M Popoli, C Vocaturo, J Perez, E Smeraldi and G Racagni
      Molecular Pharmacology October 1995, 48 (4) 623-629;

  8. Pritchard, M C

    1. Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor.
      F Z Chung, L H Wu, Y Tian, M A Vartanian, H Lee, J Bikker, C Humblet, M C Pritchard, J Raphy and N Suman-Chauhan
      Molecular Pharmacology October 1995, 48 (4) 711-716;

  9. Proska, J

    1. Competition between positive and negative allosteric effectors on muscarinic receptors.
      J Proska and S Tucek
      Molecular Pharmacology October 1995, 48 (4) 696-702;

Q

  1. Qin, Z H

    1. D2 dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D2 dopamine receptors.
      Z H Qin, L W Zhou, S P Zhang, Y Wang and B Weiss
      Molecular Pharmacology October 1995, 48 (4) 730-737;

R

  1. Racagni, G

    1. Presynaptic Ca2+/calmodulin-dependent protein kinase II: autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake.
      M Popoli, C Vocaturo, J Perez, E Smeraldi and G Racagni
      Molecular Pharmacology October 1995, 48 (4) 623-629;

  2. Raddatz, R

    1. Structural and ligand recognition properties of imidazoline binding proteins in tissues of rat and rabbit.
      B Lanier, R Raddatz, V Bakthavachalam, I Coupry, J L Neumeyer and S M Lanier
      Molecular Pharmacology October 1995, 48 (4) 703-710;

  3. Raphy, J

    1. Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor.
      F Z Chung, L H Wu, Y Tian, M A Vartanian, H Lee, J Bikker, C Humblet, M C Pritchard, J Raphy and N Suman-Chauhan
      Molecular Pharmacology October 1995, 48 (4) 711-716;

  4. Rennard, S I

    1. Lysophosphatidic acid regulation of cyclic AMP accumulation in cultured human airway smooth muscle cells.
      M Nogami, S M Whittle, D J Romberger, S I Rennard and M L Toews
      Molecular Pharmacology October 1995, 48 (4) 766-773;

  5. Romberger, D J

    1. Lysophosphatidic acid regulation of cyclic AMP accumulation in cultured human airway smooth muscle cells.
      M Nogami, S M Whittle, D J Romberger, S I Rennard and M L Toews
      Molecular Pharmacology October 1995, 48 (4) 766-773;

  6. Rosowsky, A

    1. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
      G Chen, J E Wright and A Rosowsky
      Molecular Pharmacology October 1995, 48 (4) 758-765;

S

  1. Schoepp, D D

    1. Cloning and expression of a human metabotropic glutamate receptor 1 alpha: enhanced coupling on co-transfection with a glutamate transporter.
      M A Desai, J P Burnett, N G Mayne and D D Schoepp
      Molecular Pharmacology October 1995, 48 (4) 648-657;

  2. Sebti, S M

    1. Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells.
      Z Pei, T P Calmels, C E Creutz and S M Sebti
      Molecular Pharmacology October 1995, 48 (4) 676-681;

  3. Seldon, P M

    1. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
      P M Seldon, P J Barnes, K Meja and M A Giembycz
      Molecular Pharmacology October 1995, 48 (4) 747-757;

  4. Sette, C

    1. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3.
      R Alvarez, C Sette, D Yang, R M Eglen, R Wilhelm, E R Shelton and M Conti
      Molecular Pharmacology October 1995, 48 (4) 616-622;

  5. Shelton, E R

    1. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3.
      R Alvarez, C Sette, D Yang, R M Eglen, R Wilhelm, E R Shelton and M Conti
      Molecular Pharmacology October 1995, 48 (4) 616-622;

  6. Shen, H

    1. Modulation of detoxification gene expression in human colon HT29 cells by glutathione-S-transferase inhibitors.
      P J Ciaccio, H Shen, A K Jaiswal, M H Lyttle and K D Tew
      Molecular Pharmacology October 1995, 48 (4) 639-647;

  7. Simon, J

    1. Localization of P2X purinoceptor transcripts in the rat nervous system.
      E J Kidd, C B Grahames, J Simon, A D Michel, E A Barnard and P P Humphrey
      Molecular Pharmacology October 1995, 48 (4) 569-573;

  8. Smeraldi, E

    1. Presynaptic Ca2+/calmodulin-dependent protein kinase II: autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake.
      M Popoli, C Vocaturo, J Perez, E Smeraldi and G Racagni
      Molecular Pharmacology October 1995, 48 (4) 623-629;

  9. Suman-Chauhan, N

    1. Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor.
      F Z Chung, L H Wu, Y Tian, M A Vartanian, H Lee, J Bikker, C Humblet, M C Pritchard, J Raphy and N Suman-Chauhan
      Molecular Pharmacology October 1995, 48 (4) 711-716;

T

  1. Tew, K D

    1. Modulation of detoxification gene expression in human colon HT29 cells by glutathione-S-transferase inhibitors.
      P J Ciaccio, H Shen, A K Jaiswal, M H Lyttle and K D Tew
      Molecular Pharmacology October 1995, 48 (4) 639-647;

  2. Thomas, J M

    1. Phosphorylation of cyclic AMP response element-binding protein and induction of c-fos gene expression on withdrawal from chronic treatment with carbachol in NG108-15 cells.
      J M Thomas, J S Frazier, Z W Hu and B B Hoffman
      Molecular Pharmacology October 1995, 48 (4) 593-600;

  3. Tian, Y

    1. Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor.
      F Z Chung, L H Wu, Y Tian, M A Vartanian, H Lee, J Bikker, C Humblet, M C Pritchard, J Raphy and N Suman-Chauhan
      Molecular Pharmacology October 1995, 48 (4) 711-716;

  4. Toews, M L

    1. Lysophosphatidic acid regulation of cyclic AMP accumulation in cultured human airway smooth muscle cells.
      M Nogami, S M Whittle, D J Romberger, S I Rennard and M L Toews
      Molecular Pharmacology October 1995, 48 (4) 766-773;

  5. Toftgård, R

    1. Differential effects of a topoisomerase I inhibitor on dioxin inducibility and high-level expression of the cytochrome P450IA1 gene.
      K Gradin, R Toftgård and A Berghard
      Molecular Pharmacology October 1995, 48 (4) 610-615;

  6. Tucek, S

    1. Competition between positive and negative allosteric effectors on muscarinic receptors.
      J Proska and S Tucek
      Molecular Pharmacology October 1995, 48 (4) 696-702;

V

  1. Vartanian, M A

    1. Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor.
      F Z Chung, L H Wu, Y Tian, M A Vartanian, H Lee, J Bikker, C Humblet, M C Pritchard, J Raphy and N Suman-Chauhan
      Molecular Pharmacology October 1995, 48 (4) 711-716;

  2. Vocaturo, C

    1. Presynaptic Ca2+/calmodulin-dependent protein kinase II: autophosphorylation and activity increase in the hippocampus after long-term blockade of serotonin reuptake.
      M Popoli, C Vocaturo, J Perez, E Smeraldi and G Racagni
      Molecular Pharmacology October 1995, 48 (4) 623-629;

W

  1. Wang, F

    1. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors.
      V Gerzanich, X Peng, F Wang, G Wells, R Anand, S Fletcher and J Lindstrom
      Molecular Pharmacology October 1995, 48 (4) 774-782;

  2. Wang, Y

    1. D2 dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D2 dopamine receptors.
      Z H Qin, L W Zhou, S P Zhang, Y Wang and B Weiss
      Molecular Pharmacology October 1995, 48 (4) 730-737;

  3. Warner, M

    1. Developmental and endocrine regulation of P450 isoforms in rat breast.
      H Hellmold, J G Lamb, A Wyss, J A Gustafsson and M Warner
      Molecular Pharmacology October 1995, 48 (4) 630-638;

  4. Weiss, B

    1. D2 dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D2 dopamine receptors.
      Z H Qin, L W Zhou, S P Zhang, Y Wang and B Weiss
      Molecular Pharmacology October 1995, 48 (4) 730-737;

  5. Wells, G

    1. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors.
      V Gerzanich, X Peng, F Wang, G Wells, R Anand, S Fletcher and J Lindstrom
      Molecular Pharmacology October 1995, 48 (4) 774-782;

  6. Whittle, S M

    1. Lysophosphatidic acid regulation of cyclic AMP accumulation in cultured human airway smooth muscle cells.
      M Nogami, S M Whittle, D J Romberger, S I Rennard and M L Toews
      Molecular Pharmacology October 1995, 48 (4) 766-773;

  7. Wilhelm, R

    1. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3.
      R Alvarez, C Sette, D Yang, R M Eglen, R Wilhelm, E R Shelton and M Conti
      Molecular Pharmacology October 1995, 48 (4) 616-622;

  8. Winter, M A

    1. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line.
      U G Bhat, M A Winter, H L Pearce and W T Beck
      Molecular Pharmacology October 1995, 48 (4) 682-689;

  9. Wright, J E

    1. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
      G Chen, J E Wright and A Rosowsky
      Molecular Pharmacology October 1995, 48 (4) 758-765;

  10. Wu, L H

    1. Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor.
      F Z Chung, L H Wu, Y Tian, M A Vartanian, H Lee, J Bikker, C Humblet, M C Pritchard, J Raphy and N Suman-Chauhan
      Molecular Pharmacology October 1995, 48 (4) 711-716;

  11. Wyss, A

    1. Developmental and endocrine regulation of P450 isoforms in rat breast.
      H Hellmold, J G Lamb, A Wyss, J A Gustafsson and M Warner
      Molecular Pharmacology October 1995, 48 (4) 630-638;

Y

  1. Yabaluri, N

    1. Reversible modulation of opioid receptor binding in intact neural cells by endogenous guanosine triphosphate.
      N Yabaluri and F Medzihradsky
      Molecular Pharmacology October 1995, 48 (4) 690-695;

  2. Yang, D

    1. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3.
      R Alvarez, C Sette, D Yang, R M Eglen, R Wilhelm, E R Shelton and M Conti
      Molecular Pharmacology October 1995, 48 (4) 616-622;

  3. Yellen, G

    1. A discrete site for general anesthetics on a postsynaptic receptor.
      S A Forman, K W Miller and G Yellen
      Molecular Pharmacology October 1995, 48 (4) 574-581;

Z

  1. Zhang, S P

    1. D2 dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D2 dopamine receptors.
      Z H Qin, L W Zhou, S P Zhang, Y Wang and B Weiss
      Molecular Pharmacology October 1995, 48 (4) 730-737;

  2. Zhou, L W

    1. D2 dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D2 dopamine receptors.
      Z H Qin, L W Zhou, S P Zhang, Y Wang and B Weiss
      Molecular Pharmacology October 1995, 48 (4) 730-737;

  3. Zimmerman, B J

    1. Structural requirements of analogues of polyamines for migration and growth of IEC-6 cells.
      S A McCormack, B J Zimmerman, M Israel, P Blanner and L R Johnson
      Molecular Pharmacology October 1995, 48 (4) 724-729;
Back to top

In this issue

Advertisement